Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer
Jung‐Min Lee(National Cancer Institute), Chien Chu Huang
Cited by 0
Related Papers
AKT1 interacts with DHX9 to Mitigate R Loop–Induced Replication Stress in Ovarian Cancer
|Cancer Research|2024|27